'Instrumental' Covid-19 clinical trials could be fast-tracked under new scheme
29 April 2020, 08:05
Potential Covid-19 treatments could start the clinical trials phase within weeks as part of a bid to fast-track new ways of tackling the disease.
Initially, six new drugs will be trialled under the Accelerating Covid-19 Research & Development (Accord) platform.
The platform aims to speed up the development of drugs for hospital patients diagnosed with coronavirus and it hopes to reduce the time it takes to set up clinical studies from months to weeks, according to the Department of Health and Social Care (DHSC).
The first of the potential drugs is starting phase 2 studies across the UK "imminently", the point at which a clinical trial focuses on testing a drug on patients to assess its effectiveness and any side effects, the DHSC said.
[For all the latest coronavirus news follow our live blog]
Listen & subscribe: Global Player | Apple Podcasts | Google Podcasts | Spotify
Announcing the new initiative, Health Secretary Matt Hancock said: "Currently, no drugs in the world have been clinically proven to treat Covid-19.
"But our Therapeutics Taskforce has identified a number of promising candidates.
"Currently, six different treatments have been entered into national clinical trials and the first is ready to enter the next stage: a new early phase clinical trial platform that we are launching today."
Early indications of drugs' positive results under the Accord programme, which is funded by the DHSC and UK Research and Innovation (UKRI), will see them rapidly advance to large-scale trials.
The first wave of new and existing medicines to be tested through the Accord platform are: Bemcetinib, MEDI3506 and Acalabrutinib.
Further potential treatments will be fed into Accord as the programme rolls out over the next few weeks.
It has been formed through a partnership between the Government Scientific Office, the National Institute for Health Research (NIHR)'s biomedical research centres and clinical research facilities, and expert centres in Northern Ireland, Scotland and Wales, clinical research company IQVIA and biopharmaceutical company AstraZeneca.
It comes under the overall work of the Therapeutic Taskforce, to whom the life science sector can suggest potential drugs or molecules that could be tested through the Accord platform.
Vaccine trials: Scientist explains how they work and when we can expect results
Business Secretary Alok Sharma said: "The UK is home to world-class scientists and researchers who are united in their aim to defeat coronavirus.
"Through Accord, we are bringing together the Government, industry and research organisations to speed up the development of effective new coronavirus treatments, helping to save thousands of people's lives and benefiting our NHS."
Tim Sheppard, IQVIA UK general manager and senior vice president northern Europe, said: "Covid-19 is the greatest public health challenge that has faced the world in a generation.
"Hyper-accelerating clinical trials of medicines in discovery pipelines could be instrumental in saving many lives in the UK and beyond."
